SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-084200
Filing Date
2022-03-25
Accepted
2022-03-24 20:18:08
Documents
18
Period of Report
2022-03-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d268112d8k.htm   iXBRL 8-K 32549
2 EX-1.1 d268112dex11.htm EX-1.1 175518
3 EX-5.1 d268112dex51.htm EX-5.1 9781
4 EX-99.1 d268112dex991.htm EX-99.1 8139
8 GRAPHIC g268112dsp046.jpg GRAPHIC 2420
9 GRAPHIC g268112dsp46b.jpg GRAPHIC 12507
10 GRAPHIC g268112g26l79.jpg GRAPHIC 2875
  Complete submission text file 0001193125-22-084200.txt   425968

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA apls-20220323.xsd EX-101.SCH 2858
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE apls-20220323_lab.xml EX-101.LAB 17237
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apls-20220323_pre.xml EX-101.PRE 10814
12 EXTRACTED XBRL INSTANCE DOCUMENT d268112d8k_htm.xml XML 3202
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

IRS No.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38276 | Film No.: 22767964
SIC: 2834 Pharmaceutical Preparations